# ENHANCE-3 (NCT05079230)

> Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05079230
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Gilead Sciences
- Conditions: Acute Myeloid Leukemia
- Interventions: Magrolimab; Venetoclax; Azacitidine; Placebo
- Enrollment: 378
- Primary outcome: Overall Survival (OS)

## Commentary we found

- YouTube: 5
- X threads: 5
- Podcasts: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=enhance-3-nct05079230

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05079230", "email": "<work email>"}; the inbox owner confirms by the emailed link.